Despite the challenging 2009 economy, the Intacs® SK treatment for keratoconus, which was launched internationally in 2007, performed strong throughout 2009. What originated as a concept over 30 years ago continues to succeed as the leading low-risk surgical treatment for keratoconus patients. Physicians are able to safely treat all grades of keratoconus from mild to the most severe while remaining outside the optical zone. “With Intacs SK, surgeons can present keratoconus patients with an advanced technology that has a long clinical history (over 13 years) of success”, states William M. Flynn, President & CEO of Addition Technology Inc.
Intacs and Intacs SK reshape the cornea with the goal of helping patients achieve functional vision. One of the most valuable benefits of Intacs is that the product can be exchanged or removed providing a unique comfort level to patients wanting to keep their future eye care options open. “This product is a world class performer stabilizing many unstable corneas. Medically, Intacs is the best first option before considering a more invasive corneal transplant for my contact lens intolerant patients,” says Dr. Luis Rodriguez of Venezuela. The Intacs SK product is now available through the Addition Technology network of global distributors.
Addition Technology, Inc., a privately held eye care company, specializes in novel solutions for sight-threatening eye indications. Intacs®
# # #
Addition Technology, Inc. is a privately held eye care company, specializing in novel solutions for sight-threatening eye indications.